Efficacy and Safety of Low-Dose Methotrexate in Generalized and Recalcitrant Lichen Planus: A Retrospective Study at a Tertiary Care Center

Ananta  Khurana; Savitha Sharath; Kabir Sardana

doi:10.5826/dpc.1404a220

Efficacy and Safety of Low-Dose Methotrexate in Generalized and Recalcitrant Lichen Planus: A Retrospective Study at a Tertiary Care Center

Authors

Ananta Khurana Atal Bihari Vajpayee Institute of Medical Sciences and Dr ram Manohar Lohia Hospital
Savitha Sharath Atal Bihari Vajpayee Institute of Medical Sciences and Dr ram Manohar Lohia Hospital
Kabir Sardana Atal Bihari Vajpayee Institute of Medical Sciences and Dr ram Manohar Lohia Hospital

Keywords:

methotrextae, low-dose, lichen planus, reclacitrant, relapse, adverse effects

Abstract

Introduction: Methotrexate (MTX) acts by suppressing multiple immune pathways involved in the pathogenesis of lichen planus (LP). Trials assessing the efficacy and relapse rates of methotrexate in LP are lacking.

Objectives: Our objective was to analyze the efficacy and safety of low-dose methotrexate in generalized and recalcitrant LP patients retrospectively and assess the relapse rates in patients after stopping MTX therapy.

Methods: We analyzed clinical and therapeutic details of patients of LP treated with low-dose MTX at our center. The cumulative dose and duration of MTX was calculated and the time to achieve disease control was noted. We analyzed duration of remission and time after which recurrences were seen post-treatment.

Results: A total of 42 generalized and recalcitrant LP patients treated with low-dose MTX were analyzed. A starting dose of MTX was 7.5 mg (n=7) or 10 mg (n= 35) once weekly and was increased to 10/15 mg weekly in patients with inadequate response. Ten patients were lost to follow-up. Complete resolution was achieved in 30/32 (93%) patients within a mean duration of 14.76 weeks (4-32 weeks), and the cumulative dose of MTX to achieve remission was 153.58 mg (50-375 mg). Only minor side effects were noted in 12/32 (37.5%) patients, and none required treatment discontinuation. The mean duration of remission was 29.43 months (5-60 months).

Conclusion: MTX demonstrated high efficacy and a good safety profile in extensive cutaneous LP and may be a safer alternative to steroids for the condition.

References

Hunt KM, Klager S, Kwak YJ, Sami N. Successful systemic treatment outcomes of lichen planus: A single-center retrospective review. Dermatol Ther 2021;34:e14903.

Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence- based analysis of medical treatment. J Eur Acad Dermatol Venereol 2019;33:1847-62.

Hazra SC, Choudhury AM, Khondker L, Khan SI. Comparative efficacy of methotrexate and mini pulse betamethasone in the treatment of lichen planus. Mymensingh Med J 2013;22:787–97.

Arora P, Sardana K, Gautam RK, Malhotra P. Low dose thalidomide monotherapy for the treatment of recalcitrant erosive lichen planus. Dermatol Ther 2019;32:e12824.

Sardana K, Gupta A. A recalcitrant case of ulcerative lichen planus responsive to leflunomide. Clin Exp Dermatol 2020;45:340-41.

Abduelmula A, Bagit A, Mufti A, et al. The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review. J Cutan Med Surg 2023;27:271-76.

Atzmony L, Reiter O, Hodak E, et al. Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2016;17:11-22.

Jeffes EW, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to cytotoxic and growth inhibitory effects of methotrexate. J Invest Dermatol 1995;104:183-8.

Nylander Lundqvist E, Wahlin YB, Hofer PA. Methotrexate supplemented with steroid ointments for the treatment of severe erosive lichen ruber. Acta Derm Venereol 2002;82:63-4.

Mignogna MD, Lo Russo L, Fedele S, et al. Clinical behaviour of malignant transforming oral lichen planus. Eur J Surg Oncol 2002;28: 838–43.

Ioannides D, Vakirlis E, Kemeny L, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2020;34:1403-14.

Vičić M, Hlača N, Kaštelan M, et al. Comprehensive Insight into Lichen Planus Immunopathogenesis. Int J Mol Sci 2023; 24:3038.

Sardana K. Immunosupressive drugs. In: Sardana K, Arora P, Kandhari S, Mathachan SR, Agrawal D Eds. Systemic drugs in dermatology. 2nd ed. New Delhi: Jaypee Brothers medical publishers; 2022.p.548-51.

Thomas S, Fisher KH, Snowden JA, et al. Methotrexate Is a JAK/STAT Pathway Inhibitor. PLoS One 2015;10:e0130078.

Thomas S, Fisher K, Snowden J, et al. Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. Lancet 2015;385 Suppl 1:S98.

Shao S, Tsoi LC, Sarkar MK, et al. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med 2019;11:eaav7561.

Kanwar AJ, De D. Methotrexate for treatment of lichen planus: old drug, new indication. J Eur Acad Dermatol Venereol 2013;27:e410-3.

Turan H, Baskan EB, Tunali S, et al. Methotrexate for the treatment of generalized lichen planus. J Am Acad Dermatol 2009;60:164-6.

Bakhtiar R, Noor SM, Paracha MM. Effectiveness of Oral Methotrexate Therapy versus Systemic Corticosteroid Therapy in Treatment of Generalised Lichen Planus. J Coll Physicians Surg Pak 2018;28:505-08.

Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998;134:1521-30.